SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone ...

Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key ...

Signs a strategic collaboration and license agreement to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies ...

Between January 2009 and January 2011, a total of 120 patients with LUTS due to BPH were assessed for eligibility to enter the study. All patients were subjected to the standard urologic ...

According to the American Heart Association, over 2.4 million Americans alive today have some form of congenital heart ... but when a patient undergoes a full transplant, Collins said they often ...

Scientists have identified novel genetic interactions that may contribute to congenital heart disease ... improve diagnostic yield, offering patients and their families greater clarity about ...

Growth disorders are disorders that affect the patient's height, weight and sexual development. These disorders are typically the result of atypical levels of growth hormone and patients can have ...

Patients report failed abortions, misplaced IUDs and inadequately trained staff. The health care provider of last resort is working to shore up affiliate clinics that are in dire financial straits.